A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia

PURPOSE: CPI-613, a lipoate analog that inhibits pyruvate dehydrogenase (PDH) and α-ketogluterate dehydrogenase (KGDH) has activity in patients with myeloid malignancies. This study explored the role of mitochondrial metabolism in chemotherapy response and determined the maximally tolerated dose, ef...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Pardee, Timothy S., Anderson, Rebecca G., Pladna, Kristin M., Isom, Scott, Ghiraldeli, Lais P., Miller, Lance D., Chou, Jeff W., Jin, Guangxu, Zhang, Wei, Ellis, Leslie R., Berenzon, Dmitriy, Howard, Dianna S., Hurd, David D., Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5932089/
https://ncbi.nlm.nih.gov/pubmed/29437791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados